clinicalRSVP Subject Registry Addresses Dual Enrollment
Miami, Fl – January 29, 2010 –Dual enrollment occurs when a human research subject enrolls in overlapping clinical trials without meeting protocol required washout periods. Currently, researchers have no way to verify subject washout periods and are forced to rely on a subject’s word to evaluate this component of subject eligibility.
Because some subjects participate in early phase research as a way to earn money, researchers are concerned that an incentive exists for subjects to misrepresent the last time they received a study dose in order to become enrolled in an upcoming clinical trial.
In 2009, several unaffiliated clinical research institutions in South Florida joined together to create a subject registry called clinicalRSVP that proactively safeguards against dual enrollment. A neutral administrator was commissioned, and a Web-centric database capable of tracking subjects and their dose dates was created, resulting in a way for investigators to check if a subject was recently dosed before enrolling them to an upcoming clinical trial.
Since the launch of this network in October 2009, the 5 participating sites have registered over 1,500 subjects. As a result, these sites were able, on multiple occasions, to identify recently dosed subjects attempting to screen for an upcoming trial and fairly exclude them from participating. The five sites continue to use clinicalRSVP as a way to ensure trial accuracy and encourage other sites to join as a way to increase the effectiveness of the network.
ClinicalRSVP was developed and is administered by Independent Data Integrator (IDI), a company specializing in clinical database management. IDI worked closely with the South Florida sites, along with various legal advisors and institutional review board (IRB) experts to develop the clinicalRSVP program. Plans are underway to introduce additional networks in the Midwest and Northeast.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
